Tower Research Capital LLC TRC Sells 8,096 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Tower Research Capital LLC TRC decreased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) by 69.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 3,627 shares of the company’s stock after selling 8,096 shares during the period. Tower Research Capital LLC TRC’s holdings in Pacira BioSciences were worth $193,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Pacira BioSciences by 7.4% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,930 shares of the company’s stock valued at $156,000 after acquiring an additional 203 shares during the last quarter. Arizona State Retirement System increased its position in shares of Pacira BioSciences by 2.3% in the 3rd quarter. Arizona State Retirement System now owns 12,347 shares of the company’s stock valued at $657,000 after buying an additional 275 shares in the last quarter. Martingale Asset Management L P increased its position in shares of Pacira BioSciences by 1.0% in the 2nd quarter. Martingale Asset Management L P now owns 29,712 shares of the company’s stock valued at $1,733,000 after buying an additional 291 shares in the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of Pacira BioSciences by 2.0% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 15,220 shares of the company’s stock valued at $810,000 after buying an additional 300 shares in the last quarter. Finally, Advisors Asset Management Inc. increased its position in shares of Pacira BioSciences by 32.6% in the 3rd quarter. Advisors Asset Management Inc. now owns 1,257 shares of the company’s stock valued at $67,000 after buying an additional 309 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. HC Wainwright upped their price objective on shares of Pacira BioSciences from $69.00 to $71.00 and gave the company a “buy” rating in a research report on Wednesday, March 1st. Barclays reduced their target price on shares of Pacira BioSciences from $90.00 to $80.00 in a research note on Friday. BMO Capital Markets reduced their price objective on shares of Pacira BioSciences from $60.00 to $52.00 and set a “market perform” rating for the company in a research note on Friday, January 6th. Royal Bank of Canada reduced their price objective on shares of Pacira BioSciences from $80.00 to $76.00 and set an “outperform” rating for the company in a research note on Wednesday, March 1st. Finally, Wedbush reiterated an “outperform” rating and issued a $60.00 target price on shares of Pacira BioSciences in a research note on Tuesday, January 31st. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $64.36.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX opened at $40.85 on Tuesday. The firm has a market cap of $1.88 billion, a PE ratio of 131.77 and a beta of 0.77. The firm’s fifty day moving average is $39.64 and its 200-day moving average is $46.95. The company has a debt-to-equity ratio of 0.85, a quick ratio of 2.72 and a current ratio of 3.37. Pacira BioSciences, Inc. has a 52 week low of $35.35 and a 52 week high of $82.16.

About Pacira BioSciences

(Get Rating)

Pacira Biosciences, Inc is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.